New Index Measures What Matters: Turning Science Into Cures

By Stephanie Lewis

NEW YORK, NY – April 29, 2026 – For decades, the success of biomedical research institutions has been measured by a familiar set of metrics: the size of their endowments, the volume of federal funding they attract, and the number of papers they publish in prestigious journals. Today, a new framework challenges that tradition, proposing a more impactful question: How effectively does that science actually lead to cures?

Cure, a New York-based healthcare innovation ecosystem, has launched the Cure Innovation Index, the first national data-driven effort to rank U.S. biomedical institutions on their ability to translate scientific discovery into tangible healthcare solutions. The comprehensive index evaluates 303 universities, institutes, and centers, aiming to shift the focus from academic outputs to real-world outcomes for patients.

"The Index sets a new standard for measuring translational performance across the U.S. biomedical research ecosystem, one that reflects its real and potential positive impact on patients, the healthcare system and the broader economy," said Seema Kumar, CEO of Cure. "Unlike traditional metrics, which focus on individual outputs, the Cure Innovation Index evaluates the full set of factors required to move innovation from discovery to early research to clinical and commercial impact."

A New Yardstick for Success

The Cure Innovation Index is built on a proprietary methodology that analyzes 25 distinct indicators across three core domains: Research Capabilities, which assesses foundational scientific strength; Entrepreneurial Readiness, which gauges the institutional culture and support for commercialization; and Market Translation, which evaluates the track record of moving discoveries into clinical and commercial use.

This multi-dimensional approach moves far beyond simply counting patents or publications. Instead, it integrates data from over a dozen federal and commercial databases—including ClinicalTrials.gov and the National Institutes of Health—along with original surveys of over 3,000 researchers and institutional audits. This creates a more holistic picture of what makes an institution successful at the complex journey from lab bench to patient bedside.

"Scientific excellence alone is not enough," said Thomas P. Sakmar, MD, a professor at The Rockefeller University and a key member of the Index team. "Institutions must build the infrastructure, partnerships, and culture required to translate innovation into outcomes that benefit patients." The index is a direct response to this imperative, providing a benchmark that its creators hope will make translational performance visible, comparable, and ultimately, actionable.

Powerhouses and Overachievers

The inaugural 2026 rankings separate universities from institutes and centers to reflect their different structures. The top of the university list features familiar powerhouses, with Harvard University, Stanford University, the University of Pennsylvania, Massachusetts Institute of Technology, and the University of California, San Francisco taking the top five spots. Among institutes and centers, Mass General Brigham, Mayo Clinic, and Scripps Research Institute lead the pack.

Perhaps the most compelling story from the index, however, lies not with the perennial leaders but with a group of 20 institutions identified as "punching above their weight." These are organizations that achieve an outsized translational impact relative to their federal research funding.

Leading this list is Indiana University, Indianapolis (IU Indianapolis), which ranked 49th overall in the index despite its R&D funding ranking at 177th—a staggering 128-position leap. The index suggests this success is driven by factors beyond sheer financial resources, such as robust industry partnerships and a highly effective infrastructure for moving discoveries into the real world. Similarly, Illinois Institute of Technology ranked 11th on this list, with its Vice Provost for Research, Jeff Terry, stating the recognition reflects the university's strength in translational research.

These findings suggest that while funding is important, it is not the sole determinant of success. Strategy, an embedded entrepreneurial culture, and operational efficiency in areas like technology transfer are critical drivers of impact. This offers a powerful lesson for smaller or less-resourced institutions, demonstrating that strategic focus can level the playing field in the quest to develop new cures.

From Rankings to Actionable Intelligence

Cure executives emphasize that the index is not merely a league table for academic bragging rights. It is the engine behind a sophisticated data platform designed to provide institutional leaders with diagnostic tools and strategic guidance.

Subscribing institutions can access institution-specific diagnostics, benchmark their performance against peers, identify specific gaps in their translational pipeline, and receive strategic recommendations for improvement. For a university president or research dean, this means having the data to justify investments in technology transfer offices, proof-of-concept funding, or new entrepreneurial training programs for faculty.

"The Cure Innovation Index not only measures translational research performance, but equips institutions with the tools, insights, and resources needed to continuously improve," Kumar noted.

This service model also illuminates Cure's broader strategy. As a self-described healthcare innovation ecosystem with ties to investment firm Deerfield Management, Cure is positioning itself at the center of the biomedical commercialization process. By creating the definitive metric for translational success and providing the tools to improve it, the organization is creating an invaluable resource for institutions, researchers, and investors alike, guiding capital and effort toward the most promising pathways for innovation.

A Critical Moment for American Innovation

The launch of the index comes at a pivotal time. The U.S. biomedical research ecosystem, long the global leader, faces increasing pressure from international competition. At home, there is heightened post-pandemic scrutiny on the return on investment for public research dollars and a growing demand from federal agencies for commercialization and measurable outcomes.

The Cure Innovation Index provides a new lens for understanding how institutions create value and a roadmap for how they can do better. By celebrating not just discovery but the entire, arduous process of turning that discovery into a usable therapy or medical device, the index champions a more complete and patient-centered definition of success. It is a powerful signal that in the future of healthcare, the most important question will not be what you know, but what you can do with it.